Evidence map›Paper›PMID 35831812›Full record

ArticleBMC infectious diseases2022

Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.

Ilia Bykov, Olga Dyachenko, Pavel Ratmanov, Huan Liu, Libo Liang, Qunhong Wu

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Multidrug-resistant tuberculosis.Nature reviews. Disease primers · 2024
    Review
  7. Article
  8. Article
  9. Impact of Sociodemographic Factors on the Efficacy of Multidrug-resistant Tuberculosis Therapy in Russia: Retrospective Epidemiological Study.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ilia BykovHealth Management College, Social Medicine Department, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, Heilongjiang, 10081, People's Republic of China.
Olga DyachenkoInternal Diseases Department with the Course of Phthisiology, Far Eastern State Medical University, Khabarovsk, Russia.
Pavel RatmanovPublic Health and Health Care Department, Far Eastern State Medical University, Khabarovsk, Russia.
Huan LiuHealth Management College, Social Medicine Department, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, Heilongjiang, 10081, People's Republic of China.
Libo LiangHealth Management College, Social Medicine Department, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, Heilongjiang, 10081, People's Republic of China.
Qunhong WuHealth Management College, Social Medicine Department, Harbin Medical University, 157 Baojian Road, Nangang District, Harbin, Heilongjiang, 10081, People's Republic of China. wuqunhong@163.com.
Far Eastern State Medical University · RUHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGrowing prevalence of multidrug-resistant/Rifampicin-resistant tuberculosis (MDR/RR-TB; resistance to Isoniazid and Rifampicin/Isolated resistance to Rifampicin) is putting in jeopardy the WHO End TB strategy. This study aimed to identify factors contributing to the high prevalence of MDR/RR-TB in Khabarovsk krai region of Russia.

methodsA cross-sectional retrospective study was conducted, analyzing clinical, demographic, and drug susceptibility testing data on 1440 patients. As a source of raw data, the national electronic TB surveillance system was used. Anonymous data was collected on every patient diagnosed with TB in all healthcare facilities of the region from January 2018 to December 2019. Only patients with proven excretion of m. tuberculosis were included in the study. Factors associated with MDR/RR-TB were identified through logistic regression analysis, in conjunction with in-depth interviews with eight patients, five healthcare managers and five doctors.

findings2661 patients were identified with TB, 1440 were incorporated in the study based on inclusion criteria. Of these, 618 (42.9%) were identified with MDR/RR-TB. Patients with a history of imprisonment were 16.53 times (95% CI 5.37 to 50.88,) more likely to have MDR/RR-TB, whereas re-treatment patients were 2.82 times (95% CI 2.16 to 3.66) more likely to have MDR/RR-TB. Other influencing factors included presence of disability (AOR is 2.32, 95% CI 1.38 to 3.89), cavitary disease (AOR is 1.76, 95% CI 1.37 to 2.25), and retirement status (AOR 0.65, 95% CI 0.43 to 0.98, p = 0.042). Poor patient knowledge and understanding of the disease, progressive weariness of prolonged TB treatment, and inability hospitalize infectious patients without their consent were perceived by the interviewees as major influencing factors.

conclusionsIncarceration and treatment history, regardless of outcome, were identified as major factors influencing MDR/RR-TB prevalence. It is essential for the TB care system to eliminate legal loopholes, which deprive doctors of means to enforce quarantine procedures and epidemiological surveillance on infected patients, former and current inmates. Increasing people's awareness of TB, early detection and appropriate treatment of patients with TB are needed for successfully combating MDR/RR-TB.

Indexed as

Mycobacterium tuberculosisTuberculosis, Multidrug-ResistantAntitubercular AgentsCross-Sectional StudiesHumansMicrobial Sensitivity TestsPrevalenceRetrospective StudiesRifampinAntitubercular AgentsRifampinDisabilityMultidrug-resistant/Rifampicin-resistant tuberculosisPenitentiary facilitiesRisk factorsTuberculosis

Identifiers

PMID35831812
PMCPMC9281178
OpenAlexW4285083983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.